Lilly, Ascidian Launch Up-to-$1.9B RNA Exon Editor Collaboration Targeting Inherited Kidney Diseases

PartnershipRNA exon editorPositive

AI Analysis

Summary

Eli Lilly partnered with Ascidian Therapeutics in a collaboration worth up to $1.9 billion to develop RNA exon editors for treating inherited kidney diseases, expanding Lilly's genetic medicines pipeline.

Importance:7/10

Sentiment:

0.70

partnershipgenetic medicinesRNA editinginherited kidney diseasecollaboration

Related Companies

$LLY

Read the original article

Published by GEN - Genetic Engineering & Biotech News on June 3, 2026 11:00 AM

Read Original